文献速递药物相互作用药物不良反应与药物警戒

GSK3640254与口服避孕药在健康女性中无药代动力学相互作用

Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women.
PubMed 文献 · Br J Clin Pharmacol · 2021-09-21

本研究为I期开放标签单程试验,评估HIV成熟抑制剂GSK3640254 200 mg与炔雌醇0.03 mg/左炔诺孕酮0.15 mg在健康女性中的相互作用。17名完成者中,炔雌醇和左炔诺孕酮的主要药代参数几何均值比接近1,提示无临床显著相互作用,但转氨酶升高需关注。

要点

  • GSK3640254不影响炔雌醇/左炔诺孕酮稳态药代动力学。
  • 炔雌醇AUC0-t、Cmax、Cτ几何均值比分别为0.974、0.970、1.050。
  • 左炔诺孕酮相应比值为1.069、1.032、1.083,均无临床意义。

核心结论

  • GSK3640254 200 mg与炔雌醇/左炔诺孕酮联用不影响后者的稳态药代动力学和药效学。

研究设计与样本

  • I期、开放标签、单程试验,纳入健康女性,先服炔雌醇0.03 mg/左炔诺孕酮0.15 mg 10天,后加GSK3640254 200 mg至21天。
  • 入组23人,17人完成研究。

主要发现

  • 炔雌醇AUC0-t、Cmax、Cτ的几何最小二乘均值比(联用/单用)分别为0.974、0.970、1.050。
  • 左炔诺孕酮相应比值为1.069、1.032、1.083。
  • 3例孕酮升高,其中2例发生在GSK3640254给药前;无FSH或LH升高。

临床怎么用

  • HIV阳性女性联用GSK3640254与口服避孕药时,无需调整避孕药剂量。
  • 联用期间应监测肝转氨酶,尤其注意避孕药本身可能引起转氨酶升高。

局限性

  • 开放标签设计,样本量较小(完成17例),可能影响结果外推。
  • 未报告GSK3640254的药代动力学参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: GSK3640254 is a next-generation maturation inhibitor likely to be coadministered with combined oral contraceptives in HIV-positive women. METHODS: This phase I, open-label, 1-way study assessed pharmacokinetic and pharmacodynamic interactions of GSK3640254 200 mg and ethinyl oestradiol 0.03 mg/levonorgestrel 0.15 mg once daily in healthy female participants who received ethinyl oestradiol/levonorgestrel for 10 days with a moderate-fat meal after which GSK3640254 was added from Days 11 to 21. Primary endpoints were area under the plasma concentration-time curve to the end of the dosing interval (AUC0-t ), maximum observed concentration (Cmax ) and plasma concentration at the end of the dosing interval (Cτ ) for ethinyl oestradiol and levonorgestrel. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations were determined. Adverse events were monitored. RESULTS: Among 23 enrolled participants, 17 completed the study. Geometric least squares mean ratios (with vs. without GSK3640254) of AUC0-t , Cmax and Cτ were 0.974, 0.970 and 1.050 for ethinyl oestradiol and 1.069, 1.032 and 1.083 for levonorgestrel, respectively. Three participants had elevated progesterone levels, which occurred before GSK3640254 administration in 2 participants. No participants had elevated follicle-stimulating hormone or luteinizing hormone values. Fourteen participants (61%) reported adverse events. Four participants reported asymptomatic elevated transaminase levels meeting liver-stopping criteria; of these, 3 events occurred before GSK3640254 administration and led to study withdrawal. CONCLUSION: Ethinyl oestradiol/levonorgestrel plus GSK3640254 coadministration did not affect steady-state pharmacokinetics or pharmacodynamics of ethinyl oestradiol and levonorgestrel in healthy female participants. No major tolerability findings were reported. Elevated liver transaminase levels were probably due to ethinyl oestradiol/levonorgestrel.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Pene Dumitrescu T, Greene TJ, Joshi SR, et al. Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women. Br J Clin Pharmacol. 2021. PMID: 34427938. doi:10.1111/bcp.15051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。